ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents

[1]  M. Ronot,et al.  Hepatocellular carcinoma: diagnostic criteria by imaging techniques. , 2014, Best practice & research. Clinical gastroenterology.

[2]  F. Donati,et al.  Postoperative biliary adverse events following orthotopic liver transplantation: assessment with magnetic resonance cholangiography. , 2014, World journal of gastroenterology.

[3]  Jin-Young Choi,et al.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. , 2014, Radiology.

[4]  A. Schreyer,et al.  MRI-based estimation of liver function: Gd-EOB-DTPA-enhanced T1 relaxometry of 3T vs. the MELD score , 2014, Scientific Reports.

[5]  D. Mitchell,et al.  Gadolinium contrast agent selection and optimal use for body MR imaging. , 2014, Radiologic clinics of North America.

[6]  M. Ohliger,et al.  MR imaging of diffuse liver disease: from technique to diagnosis. , 2014, Radiologic clinics of North America.

[7]  F. Miller,et al.  MR imaging of benign focal liver lesions. , 2014, Radiologic clinics of North America.

[8]  A. Schreyer,et al.  Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla , 2014, European Radiology.

[9]  B. Choi,et al.  Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging. , 2014, Radiology.

[10]  Min Ju Kim,et al.  Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid--enhanced and diffusion-weighted MR imaging with clinical-pathologic correlation. , 2014, Radiology.

[11]  A. Ba-Ssalamah,et al.  P4 radiology of hepatobiliary diseases with gadoxetic acid-enhanced MRI as a biomarker , 2014, Expert review of gastroenterology & hepatology.

[12]  S. Phongkitkarun,et al.  Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients. , 2013, World journal of gastroenterology.

[13]  Young Kon Kim,et al.  The MR imaging diagnosis of liver diseases using gadoxetic acid: Emphasis on hepatobiliary phase , 2013, Clinical and molecular hepatology.

[14]  Michael Haimerl,et al.  Added value of Gd-EOB-DTPA-enhanced Hepatobiliary phase MR imaging in evaluation of focal solid hepatic lesions , 2013, BMC Medical Imaging.

[15]  P. Wiggermann,et al.  Impact of liver cirrhosis on liver enhancement at Gd-EOB-DTPA enhanced MRI at 3 Tesla. , 2013, European journal of radiology.

[16]  F. Donati,et al.  Biliary-enteric anastomoses: spectrum of findings on Gd-EOB-DTPA-enhanced MR cholangiography , 2013, Abdominal Imaging.

[17]  P. Chow,et al.  Consensus report of the Fifth International Forum for Liver MRI. , 2013, AJR. American journal of roentgenology.

[18]  R. Semelka,et al.  Enhancement of the liver and pancreas in the hepatic arterial dominant phase: Comparison of hepatocyte‐specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 tesla MRI in the same patient , 2013, Journal of magnetic resonance imaging : JMRI.

[19]  A. Ba-Ssalamah,et al.  Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation , 2013, European Radiology.

[20]  M. Reiser,et al.  Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI. , 2013, European journal of radiology.

[21]  L. Bolondi,et al.  Impact of gadoxetic acid (Gd‐EOB‐DTPA)‐enhanced magnetic resonance on the non‐invasive diagnosis of small hepatocellular carcinoma: a prospective study , 2013, Alimentary pharmacology & therapeutics.

[22]  Young Kon Kim,et al.  Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma , 2013, Abdominal Imaging.

[23]  Carlo Bartolozzi,et al.  Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers , 2013, Abdominal Imaging.

[24]  E. Merkle,et al.  Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium. , 2012, AJR. American journal of roentgenology.

[25]  H. Hussain,et al.  Primovist, Eovist: what to expect? , 2012, Journal of hepatology.

[26]  H. C. Yu,et al.  Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT. , 2012, The British journal of radiology.

[27]  U. Motosugi,et al.  Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. , 2012, Radiology.

[28]  Myeong-Jin Kim,et al.  Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases , 2012, European Radiology.

[29]  M. Kudo.  Diagnostic Imaging of Hepatocellular Carcinoma: Recent Progress , 2011, Oncology.

[30]  C. Sirlin,et al.  Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[31]  Y. Ohno,et al.  A case of Budd-Chiari syndrome: Gd-EOB-DTPA-enhanced MR findings. , 2011, Magnetic resonance imaging.

[32]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[33]  N. Faccioli,et al.  Solid Hypervascular Liver Lesions: Accurate Identification of True Benign Lesions on Enhanced Dynamic and Hepatobiliary Phase Magnetic Resonance Imaging After Gadobenate Dimeglumine Administration , 2011, Investigative radiology.

[34]  C. Zuiani,et al.  Comparison of Portal Venous and Delayed Phases of Gadolinium-Enhanced Magnetic Resonance Imaging Study of Cirrhotic Liver for the Detection of Contrast Washout of Hypervascular Hepatocellular Carcinoma , 2010, Journal of computer assisted tomography.

[35]  S. Shankar,et al.  Focal nodular hyperplasia: Central scar enhancement pattern using gadoxetate disodium , 2010, Journal of magnetic resonance imaging : JMRI.

[36]  Elmar M Merkle,et al.  Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. , 2010, AJR. American journal of roentgenology.

[37]  D. Choi,et al.  Gadoxetic Acid (Gd-EOB-DTPA)-Enhanced MRI versus Gadobenate Dimeglumine (Gd-BOPTA)-Enhanced MRI for Preoperatively Detecting Hepatocellular Carcinoma: an Initial Experience , 2010, Korean journal of radiology.

[38]  G. Kim,et al.  Biliary MR imaging with Gd-EOB-DTPA and its clinical applications. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.

[39]  Sukru Mehmet Erturk,et al.  Use of 3.0-T MR imaging for evaluation of the abdomen. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.

[40]  Onofrio A Catalano,et al.  Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.

[41]  R. Semelka,et al.  Liver MR imaging: 1.5T versus 3T. , 2007, Magnetic resonance imaging clinics of North America.

[42]  C. Kuhl,et al.  High-field-strength MR imaging of the liver at 3.0 T: intraindividual comparative study with MR imaging at 1.5 T. , 2006, Radiology.

[43]  Jae Young Lee,et al.  Superparamagnetic Iron Oxide-Enhanced Liver Magnetic Resonance Imaging: Comparison of 1.5 T and 3.0 T Imaging for Detection of Focal Malignant Liver Lesions , 2006, Investigative radiology.

[44]  E. Merkle,et al.  Abdominal MR imaging at 3T. , 2006, Magnetic resonance imaging clinics of North America.

[45]  R. Semelka,et al.  Contrast agents for MR imaging of the liver. , 2005, Radiologic clinics of North America.

[46]  G. Morana,et al.  Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. , 2005, Radiology.

[47]  Glenn Regehr,et al.  Delphi as a method to establish consensus for diagnostic criteria. , 2003, Journal of clinical epidemiology.

[48]  M. Bellin,et al.  Currently used non-specific extracellular MR contrast media , 2003, European Radiology.

[49]  P. Meier,et al.  Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. , 1999, The Journal of pharmacology and experimental therapeutics.

[50]  G Bravo,et al.  Estimating the reliability of continuous measures with Cronbach's alpha or the intraclass correlation coefficient: toward the integration of two traditions. , 1991, Journal of clinical epidemiology.

[51]  L. Cronbach.  Coefficient alpha and the internal structure of tests , 1951 .

[52]  F. Mosteller.  Remarks on the method of paired comparisons: I. The least squares solution assuming equal standard deviations and equal correlations , 1951 .